SLR OF ECONOMIC EVALUATION FOR TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) IN UK

被引：0
|
作者：
Mehta, J. [1 ]
Harrison, O. [2 ]
Barwood, C. [3 ]
Ubi, S. [3 ]
Bertranou, E. [2 ]
Bouhlabel, F. [4 ]
Low, E. [5 ]
Shah, A. [6 ]
Korde, R. [4 ]
Shah, J. [4 ]
Gaugris, S. [3 ]
机构：
[1] Karyopharm Therapeut, Lexington, MA USA
[2] FIECON, London, Lon, England
[3] FIECON Ltd, St Albans, Hrt, England
[4] Karyopharm Therapeut, Newton, MA USA
[5] Eric Low Consulting, East Lothian, Scotland
[6] Karyopharm Therapeut, Boston, MA USA
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN165
引用
收藏
页码：S51 / S52
页数：2
相关论文
共 50 条
  • [1] Real World Evaluation of Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma (RRMM)
    Maringanti, Sireesha Asoori
    Lin, Yi
    Estritis, Stathis
    Martinez-Lopez, Joaquin
    Bansal, Radhika
    Fotiou, Despina
    Corona, Magdalena
    Chhabra, Saurabh
    Brunaldi, Larissa
    Corraes, Andre De Menezes Silva
    Parrondo, Ricardo
    Kapoor, Prashant
    Ailawadhi, Sikander
    Mas, Reyes
    Tamayo, Andrea
    Dimopoulos, Meletios
    Durie, Brian
    Martin, Thomas
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S506 - S507
  • [2] Selinexor for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
    Anum, Babar
    Hina, Zubair
    Mainoma, Bano
    Sana, Rafique
    Arzu, Shahid
    Maham, Babar
    Waleed, Madeeha S.
    Arslan, Inayat
    Danish, Safi
    AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 : S29 - S29
  • [3] SYSTEMATIC LITERATURE REVIEW (SLR) OF EVIDENCE ON THE HUMANISTIC BURDEN OF RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
    Anna, F.
    Kwon, C. S.
    Kim, M. E.
    Neuhof, A.
    Bell, T.
    Mamolo, C.
    VALUE IN HEALTH, 2020, 23 : S476 - S476
  • [4] Therapy of relapsed and/or refractory multiple myeloma (RRMM)
    Engelhardt, M.
    Waesch, R.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 14 - 14
  • [5] Real-World Evaluation of Teclistamab for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM)
    Asoori, Sireesha
    Popat, Rakesh
    Martinez-Lopez, Joaquin
    Kastritis, Efstathios
    Brunaldi, Larissa
    Bansal, Radhika
    Corraes, Andre De Menezes Silva
    Yong, Kwee
    Mactier, Catriona
    Corona, Magdalena
    Saez Marin, Adolfo Jesus
    Fotiou, Despina
    Dimopoulos, Meletios Athanasios
    Chhabra, Saurabh
    Ailawadhi, Sikander
    Parrondo, Ricardo
    Martin, Thomas
    Durie, Brian G. M.
    Lin, Yi
    BLOOD, 2023, 142
  • [6] PATIENT PREFERENCES REGARDING TREATMENT OPTIONS FOR RELAPSED REFRACTORY MULTIPLE MYELOMA (RRMM)
    Bauer, S.
    Mueller, S.
    Ratsch, B.
    Pitura, S.
    Probst, L.
    van Eickels, D.
    Wilke, T.
    VALUE IN HEALTH, 2017, 20 (09) : A451 - A451
  • [7] A SYSTEMATIC LITERATURE REVIEW (SLR) OF HEALTH STATE UTILITY VALUES (HSUVS) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
    Anna, F.
    Kim, M. E.
    Kwon, C. S.
    Bell, T.
    Mamolo, C.
    VALUE IN HEALTH, 2020, 23 : S476 - S476
  • [8] Treatment patterns among patients with relapsed/refractory multiple myeloma (RRMM) in Taiwan
    Huang, Jeffrey Shang-Yi
    Wang, Ming-Chung
    Yeh, Su-Peng
    Chen, Tsai-Yun
    Teng, Chieh-Lin Jerry
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S188 - S189
  • [9] Cost Offsets in the Treatment Journeys of Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
    Ailawadhi, Sikander
    DerSarkissian, Maral
    Duh, Mei Sheng
    Lafeuille, Marie-Helene
    Posner, George
    Ralston, Stephen
    Zagadailov, Erin
    Ba-Mancini, Abbie
    Rifkin, Robert M.
    BLOOD, 2017, 130
  • [10] Estimating the Effect of Individual Agents in the Treatment of Relapsed, Refractory Multiple Myeloma (RRMM)
    Hawkins, Neil
    Ramasamy, Karthik
    Dhanasiri, Sujith
    BLOOD, 2018, 132
12345